Cometriq cabozantinib: Additional Phase II data

Additional data from 113 evaluable patients with stage IV EGFR wild-type NSCLC who have received >=1 prior chemotherapy in the NCI-sponsored, open-label, U.S. Phase II Study E1512 showed that once-da...